Company Contents
Quick Facts & Snapshot
Summary
The Cardiac Assist Devices market is entering a scale-up phase, supported by rising heart-failure prevalence and demand for safer, more efficient circulatory support. Leading Cardiac Assist Devices market companies are consolidating share through innovation and M&A as the market grows from US$ 3.35 Billion in 2025 to US$ 5.52 Billion by 2032, reflecting a 7.40% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings of Cardiac Assist Devices market companies are based on a composite scoring framework combining quantitative and qualitative indicators. Core metrics include estimated 2025 segment revenue, multi-year revenue growth, and installed base of ventricular assist devices and intra-aortic balloon pumps. We also assess breadth of product portfolio, depth of clinical evidence, regulatory approvals, and global geographic coverage. Additional weighting is given to technology differentiation, digital integration, and hemodynamic monitoring capabilities, as well as service infrastructure and the ability to support long-term maintenance and destination-therapy programs. Strategic factors include R&D intensity, pipeline robustness, M&A activity, and success in securing major hospital system tenders. Scores are normalized and benchmarked across peers, then converted into a rank order, with cross-checks against public filings, clinical registries, and primary expert interviews to ensure objectivity and consistency.
Top 10 Companies in Cardiac Assist Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Abbott Laboratories
Abbott is the global leader in durable ventricular assist devices with a broad cardiovascular portfolio and strong hospital relationships.
Medtronic plc
Medtronic leverages its large cardiovascular footprint to offer integrated temporary cardiac assist solutions and perioperative support technologies.
Berlin Heart GmbH
Berlin Heart specializes in pediatric and adult VAD systems, holding a unique position in pediatric mechanical circulatory support.
Getinge AB (Maquet Cardiopulmonary)
Getinge delivers a wide range of intra-aortic balloon pumps and cardiopulmonary support systems integrated into critical-care workflows.
LivaNova PLC
LivaNova focuses on perfusion and temporary support solutions, positioned around the cardiac operating room and ECMO programs.
Teleflex Incorporated
Teleflex offers catheter-based access and balloon technologies, serving intra-aortic balloon pump procedures and hemodynamic interventions.
Jarvik Heart, Inc.
Jarvik Heart develops compact, continuous-flow LVADs aimed at long-term support and improved home-based patient management.
Terumo Corporation
Terumo is a prominent provider of cardiopulmonary and ECMO pumps, supplying components and systems for cardiac assist therapies.
ReliantHeart Inc.
ReliantHeart focuses on sensor-enabled LVAD systems that enable detailed remote flow monitoring and thrombus management.
CorWave SA
CorWave is an innovative European developer of wave-membrane LVADs designed to mimic physiological pulsatile blood flow.
SWOT Leaders
Abbott Laboratories
SWOT Snapshot
Market-leading LVAD installed base, extensive clinical data, broad cardiovascular ecosystem, strong global service organization.
Portfolio heavily concentrated in a single flagship LVAD platform, exposure to product-specific regulatory and safety scrutiny.
Expanding indications into earlier-stage heart failure, penetration of under-served emerging markets, integration with digital heart-failure management.
Rival LVAD innovations, pricing pressure from hospital systems, evolving reimbursement frameworks and long-term outcomes requirements.
Medtronic plc
SWOT Snapshot
Large global cardiology footprint, strong brand with hospitals, capabilities across monitoring, structural heart, and electrophysiology.
Relatively limited scale in durable LVADs, reliance on temporary support solutions and collaborative arrangements in some markets.
Bundled contracts covering devices and services, integration of support systems with monitoring platforms, expansion in high-growth emerging regions.
Intensifying competition from niche VAD innovators, regulatory delays, and cost-containment policies targeting complex cardiac procedures.
Berlin Heart GmbH
SWOT Snapshot
Unique leadership in pediatric VADs, strong relationships with transplant centers, specialized engineering know-how.
Smaller financial scale, narrower product range, relatively concentrated geographic exposure compared with multinationals.
Growing recognition of pediatric heart-failure care, internationalization of transplant programs, and support for rare-disease technologies.
Entry of larger players into pediatric niches, reimbursement constraints in smaller markets, and clinical preference shifts to alternative therapies.
Cardiac Assist Devices Market Regional Competitive Landscape
North America remains the largest regional market, driven by high heart-failure prevalence, advanced transplant programs, and strong reimbursement frameworks. Abbott Laboratories and Medtronic plc are the dominant Cardiac Assist Devices market companies, supported by deep relationships with large integrated delivery networks and academic centers, while niche players like Jarvik Heart and ReliantHeart Inc. focus on specialized LVAD segments.
Europe shows robust but heterogeneous adoption, with Germany, the United Kingdom, France, and the Nordics leading LVAD and ECMO utilization. Berlin Heart GmbH and CorWave SA benefit from proximity to key university hospitals and transplant centers. Getinge AB and LivaNova PLC leverage strong OR and ICU installed bases to sell temporary support and perfusion-linked solutions across Western and Northern Europe.
Asia-Pacific is the fastest-growing region, underpinned by rising cardiovascular burden, expanding tertiary-care infrastructure, and improving reimbursement in markets such as China, Japan, South Korea, and India. Terumo Corporation and Getinge AB are well-positioned in ECMO and cardiopulmonary support. Global Cardiac Assist Devices market companies increasingly form training partnerships with flagship centers in China and Southeast Asia to accelerate adoption.
The Middle East and Latin America are emerging growth frontiers, with high demand concentrated in a limited number of well-funded cardiac centers. Getinge AB, LivaNova PLC, and Medtronic plc frequently win tenders for IABP, ECMO, and perfusion systems. Market penetration of durable LVADs remains comparatively low, constrained by affordability, specialized staffing needs, and transplant availability.
In Eastern Europe and parts of Africa, the Cardiac Assist Devices market is nascent but gradually developing through international collaborations and donor-funded capacity-building programs. Leading Cardiac Assist Devices market companies typically enter via flagship reference centers, offering training-driven deployment of IABP and ECMO first, with LVAD adoption following as surgical capabilities, data infrastructure, and reimbursement frameworks mature.
Cardiac Assist Devices Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Developing the ICOMS FLOWMAKER, a minimally invasive fully implantable device aiming to reduce complications versus conventional LVADs.
Building magnetically levitated VADs and ECMO pumps, targeting cost-effective, high-performance solutions for rapidly growing Asian cardiac centers.
Pioneering wireless power transfer systems for LVADs, reducing driveline infection risk and supporting untethered patient mobility at home.
Developing a total artificial heart based on rotary disk technology, addressing end-stage biventricular failure beyond current LVAD scope.
Offers LVAD solutions emphasizing pulsatile-like flow and improved hemocompatibility, targeting both domestic and international transplant programs.
Cardiac Assist Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Cardiac Assist Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Cardiac Assist Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.